U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07594899) titled 'AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL' on May 05.
Brief Summary: This is a prospective, open-label, multicenter, randomized controlled study in participants with previously untreated large B-cell lymphoma. Participants will be stratified into different risk groups using an AI-based multimodal model. Those classified as intermediate- or high-risk will be randomized in a 1:1 ratio to receive either an AI-guided treatment strategy or Pola-R-CHP. In the experimental arm, participants will receive either genotype-guided targeted agents in combination with Pola-R-CHP or Pola-R-CHP combined with glofitamab, according ...